Sponsored By:

4 Pharmaceutical Stocks to Buy Now

JNJ, BMY, WPI, RPRX improve in weekly rankings

   

This week, four Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Johnson & Johnson (NYSE:JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.

Bristol-Myers Squibb Company (NYSE:BMY) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Shares of BMY have increased 11.5% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.

This is a strong week for Watson Pharmaceuticals (NYSE:WPI). The company’s rating climbs to A from the previous week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Repros Therapeutics (NASDAQ:RPRX) is seeing ratings go up from a B last week to an A this week. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 38% over the past month. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/09/4-pharmaceutical-stocks-to-buy-now-jnj-bmy-wpi-23/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.